Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 8/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835948 | 0.93 | CSNK1E (0.45) | CSNK1ECSNK1DPIK3CAMTORPTK2 | |
| SCHEMBL30590462 | 0.91 | CSNK1E (0.45) | CSNK1ECSNK1DPIK3CATACR2TRPV1 | |
| SCHEMBL30590496 | 0.90 | CSNK1E (0.43) | CSNK1ECSNK1DKCNH2SCN9A | |
| SCHEMBL30590492 | 0.90 | CSNK1E (0.44) | CSNK1ECSNK1DPIK3CAMTORCDK13 | |
| SCHEMBL25299368 | 0.90 | CSNK1E (0.44) | CSNK1ECSNK1DPIK3CAMTORCDK13 | |
| SCHEMBL25303708 | 0.87 | CSNK1D (0.42) | CSNK1ECSNK1DPIK3CAMTORPTK2 | |
| SCHEMBL30590445 | 0.87 | PIK3CA (0.40) | CSNK1ECSNK1DPIK3CATACR2TRPV1 | |
| SCHEMBL23508542 | 0.82 | CSNK1E (0.48) | CSNK1ECSNK1D | |
| SCHEMBL23497864 | 0.81 | CSNK1E (0.50) | CSNK1ECSNK1DPIK3CAMTORCDK13 | |
| SCHEMBL30590457 | 0.81 | CSNK1E (0.43) | CSNK1ECSNK1DKCNH2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCH (DE) | 2025-02-27 | — | — | US | claimed |
| CN-118541372-A | Bicyclic triazine derivatives for the treatment of cancer | 德国癌症研究中心 | 2024-08-23 | — | — | CN | claimed |
| WO-2023135057-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-07-20 | — | — | WO | claimed |
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCH (DE) | 2025-02-27 | — | — | US | disclosed |
| EP-4463458-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-118541372-A | Bicyclic triazine derivatives for the treatment of cancer | 德国癌症研究中心 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023135057-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | BRCA1, CCNY, CCND2 | CSNK1E 2203/4885CSNK1D 1943/4885PIK3CA 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.